• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

持续性炎症-免疫抑制-分解代谢综合征(PICS)中的炎症反应与抗炎治疗

Inflammatory Response and Anti-Inflammatory Treatment in Persistent Inflammation-Immunosuppression-Catabolism Syndrome (PICS).

作者信息

Xiong Dacheng, Geng Huixian, Lv Xuechun, Wang Shuqi, Jia Lijing

机构信息

Department of Intensive Care Medicine, Hebei Medical University, Shijiazhuang, People's Republic of China.

Department of Intensive Care Medicine, Hebei General Hospital, Shijiazhuang, People's Republic of China.

出版信息

J Inflamm Res. 2025 Feb 14;18:2267-2281. doi: 10.2147/JIR.S504694. eCollection 2025.

DOI:10.2147/JIR.S504694
PMID:39968098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11834740/
Abstract

Many patients now survive their initial critical events but subsequently develop chronic critical illness (CCI). CCI is characterized by prolonged hospital stays, poor outcomes, and significant long-term mortality. The incidence of chronic critical illness (CCI) is estimated to be 34.4 cases per 100,000 population. The incidence varies significantly with age, peaking at 82.1 cases per 100,000 in individuals aged 75-79. The one-year mortality rate among CCI patients approaches 50%. A subset of these patients enters a state of persistent inflammation, immune suppression, and ongoing catabolism, a condition termed persistent inflammation, immunosuppression, and catabolism syndrome (PICS) in 2012. In recent years, some progress has been made in treating PICS. For instance, recent advancements such as the persistent expansion of MDSCs (myeloid-derived suppressor cells) and the mechanisms underlying intestinal barrier dysfunction have provided new directions for therapeutic strategies, as discussed below. Persistent inflammation, a key feature of PICS, has received comparatively little research attention. In this review, we examine the potential pathophysiological changes and molecular mechanisms underlying persistent inflammation and its role in PICS. We also discuss current therapies about inflammation and offer recommendations for managing patients with PICS.

摘要

现在许多患者在经历最初的危急事件后存活下来,但随后发展为慢性危重病(CCI)。慢性危重病的特征是住院时间延长、预后不良以及长期死亡率高。据估计,慢性危重病(CCI)的发病率为每10万人中有34.4例。发病率随年龄显著变化,在75 - 79岁的人群中达到峰值,每10万人中有82.1例。慢性危重病患者的一年死亡率接近50%。这些患者中的一部分进入持续炎症、免疫抑制和持续分解代谢状态,2012年将这种情况称为持续炎症、免疫抑制和分解代谢综合征(PICS)。近年来,在治疗PICS方面取得了一些进展。例如,最近的进展,如骨髓来源的抑制细胞(MDSCs)的持续扩增以及肠道屏障功能障碍的潜在机制,为治疗策略提供了新的方向,如下所述。持续炎症是PICS的一个关键特征,但相对较少受到研究关注。在这篇综述中,我们研究了持续炎症潜在的病理生理变化和分子机制及其在PICS中的作用。我们还讨论了当前针对炎症的治疗方法,并为管理PICS患者提供建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b53/11834740/5cb5fbb0c765/JIR-18-2267-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b53/11834740/6a26cad70ced/JIR-18-2267-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b53/11834740/5cb5fbb0c765/JIR-18-2267-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b53/11834740/6a26cad70ced/JIR-18-2267-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b53/11834740/5cb5fbb0c765/JIR-18-2267-g0002.jpg

相似文献

1
Inflammatory Response and Anti-Inflammatory Treatment in Persistent Inflammation-Immunosuppression-Catabolism Syndrome (PICS).持续性炎症-免疫抑制-分解代谢综合征(PICS)中的炎症反应与抗炎治疗
J Inflamm Res. 2025 Feb 14;18:2267-2281. doi: 10.2147/JIR.S504694. eCollection 2025.
2
Hypercatabolism and Anti-catabolic Therapies in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome.持续性炎症、免疫抑制和分解代谢综合征中的高分解代谢与抗分解代谢疗法
Front Nutr. 2022 Jul 13;9:941097. doi: 10.3389/fnut.2022.941097. eCollection 2022.
3
Persistent inflammation, immunosuppression, and catabolism syndrome (PICS): a review of definitions, potential therapies, and research priorities.持续炎症、免疫抑制和分解代谢综合征(PICS):定义、潜在治疗方法和研究重点的综述。
Br J Anaesth. 2024 Mar;132(3):507-518. doi: 10.1016/j.bja.2023.11.052. Epub 2024 Jan 4.
4
Innate Immunity in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and Its Implications for Therapy.固有免疫在持续炎症、免疫抑制和分解代谢综合征中的作用及其治疗意义。
Front Immunol. 2018 Apr 4;9:595. doi: 10.3389/fimmu.2018.00595. eCollection 2018.
5
Chronic Critical Illness and PICS Nutritional Strategies.慢性危重病与危重症后综合征营养策略
J Clin Med. 2021 May 25;10(11):2294. doi: 10.3390/jcm10112294.
6
[Persistent inflammation immunosuppression catabolism syndrome: a special type of chronic critical illness].持续性炎症-免疫抑制-分解代谢综合征:一种特殊类型的慢性危重病
Zhonghua Wei Chang Wai Ke Za Zhi. 2016 Jul;19(7):734-6.
7
Risk factors, biomarkers, and mechanisms for persistent inflammation, immunosuppression, and catabolism syndrome (PICS): a systematic review and meta-analysis.持续炎症、免疫抑制和分解代谢综合征(PICS)的风险因素、生物标志物和机制:系统评价和荟萃分析。
Br J Anaesth. 2024 Sep;133(3):538-549. doi: 10.1016/j.bja.2024.03.038. Epub 2024 Apr 30.
8
Older Adults Demonstrate Biomarker Evidence of the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome (PICS) After Sepsis.老年人在脓毒症后表现出持续性炎症、免疫抑制和分解代谢综合征(PICS)的生物标志物证据。
J Gerontol A Biol Sci Med Sci. 2022 Jan 7;77(1):188-196. doi: 10.1093/gerona/glab080.
9
Chronic Critical Illness and the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome.慢性危重病与持续性炎症、免疫抑制和分解代谢综合征
Front Immunol. 2018 Jul 2;9:1511. doi: 10.3389/fimmu.2018.01511. eCollection 2018.
10
Biomarker Evidence of the Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS) in Chronic Critical Illness (CCI) After Surgical Sepsis.慢性外科术后脓毒症患者持续性炎症、免疫抑制和分解代谢综合征(PICS)的生物标志物证据。
Ann Surg. 2021 Oct 1;274(4):664-673. doi: 10.1097/SLA.0000000000005067.

本文引用的文献

1
From bedside to recovery: exercise therapy for prevention of post-intensive care syndrome.从床边到康复:运动疗法预防重症监护后综合征
J Intensive Care. 2024 Feb 29;12(1):11. doi: 10.1186/s40560-024-00724-4.
2
The total mass, number, and distribution of immune cells in the human body.人体中免疫细胞的总质量、数量和分布。
Proc Natl Acad Sci U S A. 2023 Oct 31;120(44):e2308511120. doi: 10.1073/pnas.2308511120. Epub 2023 Oct 23.
3
Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial.
静脉注射白细胞介素-7逆转感染性休克患者淋巴细胞减少症:一项双盲、随机、安慰剂对照试验。
Ann Intensive Care. 2023 Mar 12;13(1):17. doi: 10.1186/s13613-023-01109-w.
4
Alleviates Persistent Inflammation, Immunosuppression, and Catabolism Syndrome in Mice.减轻小鼠的持续性炎症、免疫抑制和分解代谢综合征。
Metabolites. 2023 Jan 28;13(2):194. doi: 10.3390/metabo13020194.
5
From (Tool)Bench to Bedside: The Potential of Necroptosis Inhibitors.从(工具)实验室到病床:坏死性凋亡抑制剂的潜力。
J Med Chem. 2023 Feb 23;66(4):2361-2385. doi: 10.1021/acs.jmedchem.2c01621. Epub 2023 Feb 13.
6
Can pioglitazone be used for optimization of nutrition in critical illness? A systematic review.吡格列酮可否用于危重症患者的营养优化?系统评价。
JPEN J Parenter Enteral Nutr. 2023 May;47(4):459-475. doi: 10.1002/jpen.2481. Epub 2023 Feb 22.
7
Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial.迈向脓毒症个体化免疫治疗:PROVIDE 随机临床试验。
Cell Rep Med. 2022 Nov 15;3(11):100817. doi: 10.1016/j.xcrm.2022.100817.
8
Monitoring of circulating monocyte HLA-DR expression in a large cohort of intensive care patients: relation with secondary infections.在一大群重症监护患者中监测循环单核细胞 HLA - DR 表达:与继发感染的关系
Ann Intensive Care. 2022 May 8;12(1):39. doi: 10.1186/s13613-022-01010-y.
9
Association of monocyte HLA-DR expression over time with secondary infection in critically ill children: a prospective observational study.随时间推移单核细胞 HLA-DR 表达与危重症患儿继发感染的相关性:一项前瞻性观察研究。
Eur J Pediatr. 2022 Mar;181(3):1133-1142. doi: 10.1007/s00431-021-04313-7. Epub 2021 Nov 10.
10
Regulatory T cells function in established systemic inflammation and reverse fatal autoimmunity.调节性 T 细胞在已建立的全身炎症中发挥作用,并逆转致命的自身免疫。
Nat Immunol. 2021 Sep;22(9):1163-1174. doi: 10.1038/s41590-021-01001-4. Epub 2021 Aug 23.